Acute effects of ayahuasca on neuropsychological performance: Differences in executive function between experienced and occasional users

Psychopharmacology

Volumn 230, Issue 3, 2013, Pages 415-424

  Bouso, José Carlos ^a,b,c,e   Fábregas, Josep Maria ^f,g   Antonijoan, Rosa Maria ^b,c,d   Rodríguez Fornells, Antoni ^h,i,j   Riba, Jordi ^a,b,c,d  

^a BIOMEDICAL RESEARCH INSTITUTE SANT PAU IIB SANT PAU   (Spain)

^b HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^c UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^d CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE SALUD MENTAL CIBERSAM   (Spain)

^e International Center for Ethnobotanical Education Research and Service   (Netherlands)

^f Centre d'Investigació i Tractament d'Addiccions CITA   (Spain)

^g Institut d'Etnospicologia Amazonica Aplicada   (Brazil)

^h BELLVITGE BIOMEDICAL RESEARCH INSTITUTE IDIBELL   (Spain)

ⁱ UNIVERSITY OF BARCELONA   (Spain)

^j INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS ICREA   (Spain)

more..

Author keywords

Ayahuasca; Executive functions; Neuropsychology; Psychedelics

Indexed keywords

AYAHUASCA; N,N DIMETHYLTRYPTAMINE; PSYCHEDELIC AGENT; SEROTONIN 2A AGONIST; UNCLASSIFIED DRUG;

ACCURACY; ADULT; ARTICLE; BRAIN BLOOD FLOW; CONTROLLED STUDY; CORRELATION ANALYSIS; EXECUTIVE FUNCTION; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; NEUROPSYCHOLOGICAL TEST; PERSONAL EXPERIENCE; PLANT; PRIORITY JOURNAL; STROOP TEST; WORKING MEMORY;

ADULT; BANISTERIOPSIS; COGNITION; DRUG USERS; EXECUTIVE FUNCTION; FEMALE; HALLUCINOGENS; HUMANS; MALE; MEMORY, SHORT-TERM; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; REACTION TIME; TEA; TIME FACTORS;

EID: 84888646649     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-013-3167-9     Document Type: Article

References (76)

1. Abdullaev Y, Posner MI, Nunnally R, Dishion TJ (2010) Functional MRI evidence for inefficient attentional control in adolescent chronic cannabis abuse. Behav Brain Res 215:45-57
2. Aghajanian GK, Marek GJ (1997) Serotonin induces excitatory postsynaptic potentials in apical dendrites of neocortical pyramidal cells. Neuropharmacol 36:589-599
3. Béïque JC, Imad M, Mladenovic L, Gingrich JA, Andrade R (2007) Mechanism of the 5-hydroxytryptamine 2A receptor-mediated facilitation of synaptic activity in prefrontal cortex. Proc Natl Acad Sci U S A 104:9870-9875
4. Bouso JC, González D, Fondevila S, Cutchet M, Fernández X, Ribeiro Barbosa PC, Alcázar-Córcoles MÁ, Araújo WS, Barbanoj MJ, Fábregas JM, Riba J (2012) Personality, psychopathology, life attitudes, and neuropsychological performance among ritual users of ayahuasca: a longitudinal study. PLOS ONE 7:e42421
5. Bramham CR, Messaoudi E (2005) BDNF function in adult synaptic plasticity: the synaptic consolidation hypothesis. Prog Neurobiol 76:99-125
6. Carhart-Harris RL, Leech R, Erritzoe D, Williams TM, Stone JM, Evans J, Sharp DJ, Feilding A, Wise RG, Nutt DJ (2012a) Functional connectivity measures after psilocybin inform a novel hypothesis of early psychosis. Schizophr Bull. doi: 10.1093/schbul/sbs117
7. Carhart-Harris RL, Erritzoe D, Williams T, Stone JM, Reed LJ, Colasanti A, Tyacke RJ, Leech R, Malizia AL, Murphy K, Hobden P, Evans J, Feilding A, Wise RG, Nutt DJ (2012b) Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin. Proc Natl Acad Sci USA 109(6):2138-2143
8. Carter CS, van Veen V (2007) Anterior cingulate cortex and conflict detection: an update of theory and data. Cogn Affect Behav Neurosci 7:367-379
9. Carter OL, Pettigrew JD, Burr DC, Alais D, Hasler F, Vollenweider FX (2004) Psilocybin impairs high-level but not low-level motion perception. Neuroreport 15:1947-1951
10. Carter OL, Burr DC, Pettigrew JD, Wallis GM, Hasler F, Vollenweider FX (2005a) Using psilocybin to investigate the relationship between attention, working memory, and the serotonin 1A and 2A receptors. J Cogn Neurosci 17:1497-1508
11. Carter OL, Pettigrew JD, Hasler F, Wallis GM, Liu GB, Hell D, Vollenweider FX (2005b) Modulating the rate and rhythmicity of perceptual rivalry alternations with the mixed 5-HT2A and 5-HT1A agonist psilocybin. Neuropsychopharmacology 30:1154-1162
12. Carter OL, Hasler F, Pettigrew JD, Wallis GM, Liu GB, Vollenweider FX (2007) Psilocybin links binocular rivalry switch rate to attention and subjective arousal levels in humans. Psychopharmacology (Berl) 195:415-424
13. Daumann J, Heekeren K, Neukirch A, Thiel CM, Möller-Hartmann W, Gouzoulis-Mayfrank E (2008) Pharmacological modulation of the neural basis underlying inhibition of return (IOR) in the human 5-HT2A agonist and NMDA antagonist model of psychosis. Psychopharmacology (Berl) 200:573-583
14. Daumann J, Wagner D, Heekeren K, Neukirch A, Thiel CM, Gouzoulis-Mayfrank E (2010) Neuronal correlates of visual and auditory alertness in the DMT and ketamine model of psychosis. J Psychopharmacol 24:1515-1524
15. de Almeida J, Mengod G (2007) Quantitative analysis of glutamatergic and GABAergic neurons expressing 5-HT(2A) receptors in human and monkey prefrontal cortex. J Neurochem 103:475-486
16. D'Esposito M, Postle BR, Rypma B (2000) Prefrontal cortical contributions to working memory: evidence from event-related fMRI studies. Exp Brain Res 133:3-11
17. del Ser T, García-Montalvo JI, Martínez Espinosa S, Delgado-Villapalos C, Bermejo F (1997) The estimation of premorbid intelligence in Spanish people with the "Word Accentuation Test" and its application to the diagnosis of dementia. Brain Cogn 33:343-356
18. Dockery CA, Hueckel-Weng R, Birbaumer N, Plewnia C (2009) Enhancement of planning ability by transcranial direct current stimulation. J Neurosci 29:7271-7277
19. dos Santos R, Valle M, Bouso JC, Nomdedéu JF, Rodríguez- Espinosa J, McIlhenny EH, Barker SA, Barbanoj MJ, Riba J (2011) Autonomic, neuroendocrine, and immunological effects of ayahuasca: a comparative study with d-amphetamine. J Clin Psychopharmacol 31:717-726
20. dos Santos RG, Grasa E, Valle M, Ballester MR, Bouso JC, Nomdedéu JF, Homs R, Barbanoj MJ, Riba J (2012) Pharmacology of ayahuasca administered in two repeated doses. Psychopharmacology (Berl) 219:1039-1053
21. Frankel PS, Cunningham KA (2002) The hallucinogen d-lysergic acid diethylamide (d-LSD) induces the immediate-early gene c-Fos in rat forebrain. Brain Res 958:251-260
22. Frecska E, White KD, Luna LE (2004) Effects of ayahuasca on binocular rivalry with dichoptic stimulus alternation. Psychopharmacology (Berl) 173:79-87
23. Geyer MA, Vollenweider FX (2008) Serotonin research: contributions to understanding psychoses. Trends Pharmacol Sci 29:445-453
24. Gewirtz JC, Chen AC, Terwilliger R, Duman RC, Marek GJ (2002) Modulation of DOI-induced increases in cortical BDNF expression by group II mGlu receptors. Pharmacol Biochem Behav 73:317-326
25. Golden CJ (1978) Stroop color and word test. A manual for clinical and experimental uses. Illinois: Stoelting Co, Wood Dale
26. González-Maeso J, Sealfon SC (2009a) Psychedelics and schizophrenia. Trends Neurosci 32:225-232
27. González-Maeso J, Sealfon SC (2009b) Agonist-trafficking and hallucinogens. Curr Med Chem 16:1017-1027
28. Gouzoulis-Mayfrank E, Habermeyer E, Hermle L, Steinmeyer A, Kunert H, Sass H (1998a) Hallucinogenic drug-induced states resemble acute endogenous psychoses: results of an empirical study. Eur Psychiatry 13:399-406
29. Gouzoulis-Mayfrank E, Heekeren K, Thelen B, Lindenblatt H, Kovar KA, Sass H, Geyer MA (1998b) Effects of the hallucinogen psilocybin on habituation and prepulse inhibition of the startle reflex in humans. Behav Pharmacol 9:561-566
30. Gouzoulis-Mayfrank E, Schreckenberger M, Sabri O, Arning C, Thelen B, Spitzer M, Kovar KA, Hermle L, Büll U, Sass H. (1999a) Neurometabolic effects of psilocybin, 3,4-methylenedioxyethylamphetamine (MDE) and d-methamphetamine in healthy volunteers. A double-blind, placebo-controlled PET study with [18F]FDG. Neuropsychopharmacology 20:565-81
31. Gouzoulis-Mayfrank E, Thelen B, Habermeyer E, Kunert HJ, Kovar KA, Lindenblatt H, Hermle L, Spitzer M, Sass H (1999b) Psychopathological, neuroendocrine, and autonomic effects of 3,4-methylenedioxyethylamphetamine (MDE), psilocybin and d-methamphetamine in healthy volunteers. Results of an experimental double-blind placebo-controlled study. Psychopharmacology (Berl) 142:41-50
32. Gouzoulis-Mayfrank E, Thelen B, Maier S, Heekeren K, Kovar KA, Sass H, Spitzer M (2002) Effects of the hallucinogen psilocybin on covert orienting of visual attention in humans. Neuropsychobiology 45:205-212
33. Gouzoulis-Mayfrank E, Heekeren K, Neukirch A, Stoll M, Stock C, Daumann J, Obradovic M, Kovar KA (2006) Inhibition of return in the human 5HT2A agonist and NMDA antagonist model of psychosis. Neuropsychopharmacology 31:431-441
34. Gresch PJ, Strickland LV, Sanders-Bush E (2002) Lysergic acid diethylamide-induced Fos expression in rat brain: role of serotonin-2A receptors. Neuroscience 114:707-713
35. Halberstadt AL, Koedood L, Powell SB, Geyer MA (2011) Differential contributions of serotonin receptors to the behavioral effects of indoleamine hallucinogens in mice. J Psychopharmacol 25:1548-1561
36. Hannon J, Hoyer D (2008) Molecular biology of 5-HT receptors. Behav Brain Res 195:198-213
37. Harding IH, Solowij N, Harrison BJ, Takagi M, Lorenzetti V, Lubman DI, Seal ML, Pantelis C, Yücel M (2012) Functional connectivity in brain networks underlying cognitive control in chronic cannabis users. Neuropsychopharmacology 37:1923-1933
38. Hart CL, van Gorp W, Haney M, Foltin RW, Fischman MW (2001) Effects of acute smoked marijuana on complex cognitive performance. Neuropsychopharmacology 25:757-765
39. Hart CL, Ilan AB, Gevins A, Gunderson EW, Role K, Colley J, Foltin RW (2010) Neurophysiological and cognitive effects of smoked marijuana in frequent users. Pharmacol Biochem Behav 96:333-341
40. Hasler F, Grimberg U, Benz MA, Huber T, Vollenweider FX (2004) Acute psychological and physiological effects of psilocybin in healthy humans: a double-blind, placebo-controlled dose-effect study. Psychopharmacology (Berl) 172:145-156
41. Heekeren K, Daumann J, Neukirch A, Stock C, Kawohl W, Norra C, Waberski TD, Gouzoulis-Mayfrank E (2008) Mismatch negativity generation in the human 5HT2A agonist and NMDA antagonist model of psychosis. Psychopharmacology (Berl) 199:77-88
42. Hermle L, Fünfgeld M, Oepen G, Botsch H, Borchardt D, Gouzoulis E, Fehrenbach RA, Spitzer M (1992) Mescaline-induced psychopathological, neuropsychological, and neurometabolic effects in normal subjects: experimental psychosis as a tool for psychiatric. Biol Psychiatry 32:976-991
43. Jocham G, Ullsperger M (2009) Neuropharmacology of performance monitoring. Neurosci Biobehav Rev 33:48-60
44. Kirschen MP, Chen SH, Desmond JE (2010) Modality specific cerebrocerebellar activations in verbal working memory: an fMRI study. Behav Neurol 23:51-63
45. Klodzinska A, Bijak M, Tokarski K, Pilc A (2002) Group II mGlu receptor agonists inhibit behavioral and electrophysiological effects of DOI in mice. Pharmacol Biochem Behav 73:327-332
46. Kometer M, Cahn BR, Andel D, Carter OL, Vollenweider FX (2011) The 5-HT2A/1A agonist psilocybin disrupts modal object completion associated with visual hallucinations. Biol Psychiatry 69:399-406
47. Lazaron RHC, Rombouts SARB, Machielsen WCM, Scheltens P, Menno P, Witter Uylings HBM, Barkhof F (2000) Visualizing brain activation during planning: The Tower of London Test adapted for functional MR imaging, AJNR Am. J Neuroradiol 21:1407-1414
48. Lane HY, Liu YC, Huang CL, Hsieh CL, Chang YL, Chang L, Chang YC, Chang WH (2008) Prefrontal executive function and D1, D3, 5-HT2A, and 5-HT6 receptor gene variations in healthy adults. J Psychiatry Neurosci 33:47-53
49. Miller EK, Cohen JD (2001) An integrative theory of prefrontal cortex function. Annu Rev Neurosci 24:167-202
50. Nelson H, O'Connell A (1978) Dementia: the estimation of premorbid intelligence levels using the new Adult Reading Test. Cortex 14:234-244
51. Passetti F, Dalley JW, Robbins TW (2003) Double dissociation of serotonergic and dopaminergic mechanisms on attentional performance using a rodent five-choice reaction time task. Psychopharmacology (Berl) 165:136-145
52. Riba J (2003) Human Pharmacology of Ayahuasca, doctoral thesis, Universitat Autònoma de Barcelona, 2003. http://www.tdx.cat/handle/10803/ 5378 [23 January 2013].
53. Riba J, Rodríguez-Fornells A, Urbano G, Morte A, Antonijoan R, Montero M, Callaway JC, Barbanoj MJ (2001) Subjective effects and tolerability of the South American psychoactive beverage ayahuasca in healthy volunteers. Psychopharmacology 154:85-95
54. Riba J, Anderer P, Morte A, Urbano G, Jane F, Saletu B, Barbanoj MJ (2002) Topographic pharmaco-EEG mapping of the effects of the South American psychoactive beverage ayahuasca in healthy volunteers. Br J Clin Pharmacol 53:613-628
55. Riba J, Valle M, Urbano G, Yritia M, Morte A, Barbanoj MJ (2003) Human pharmacology of ayahuasca: subjective and cardiovascular effects, monoamine metabolite excretion, and pharmacokinetics. J Pharmacol Exp Ther 306:73-83
56. Riba J, Romero S, Grasa E, Mena E, Carrió I, Barbanoj MJ (2006) Increased frontal and paralimbic activation following ayahuasca, the pan-Amazonian inebriant. Psychopharmacology (Berl) 186:93-98
57. Robbins TW, Arnsten AF (2009) The neuropsychopharmacology of fronto-executive function: monoaminergic modulation. Annu Rev Neurosci 32:267-287
58. Schall U et al (2003) Functional brain maps of Tower of London performance: a positron emission tomography and functional magnetic resonance imaging study. NeuroImage 20:1154-1161
59. Shallice T (1982) Specific impairments of planning. Phil Trans R Soc Lond 298:199-209
60. Soulé J, Messaoudi E, Bramham CR (2006) Brain-derived neurotrophic factor and control of synaptic consolidation in the adult brain. Biochem Soc Trans 34:600-604
61. Spitzer M, Thimm M, Hermle L, Holzmann P, Kovar KA, Heimann H, Gouzoulis-Mayfrank E, Kischka U, Schneider F (1996) Increased activation of indirect semantic associations under psilocybin. Biol Psychiatry 39:1055-1057
62. Sternberg S (1966) High-speed scanning in human memory. Science 153:652-654
63. Strassman RJ, Qualls CR, Uhlenhuth EH, Kellner R (1994) Dose-response study of N, N-dimethyltryptamine in humans, II. Subjective effects and preliminary results of a new rating scale. Arch Gen Psychiatry 51:98-108
64. Studerus E, Kometer M, Hasler F, Vollenweider FX (2011) Acute, subacute, and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies. J Psychopharmacol 25:1434-1452
65. Strauss E, Sherman EMS, Spreen O (2006) A compendium of neuropsychological tests: administration, norms, and commentary. Oxford University Press, Oxford; New York
66. Tapert SF, Schweinsburg AD, Drummond SP, Paulus MP, Brown SA, Yang TT, Frank LR (2007) Functional MRI of inhibitory processing in abstinent adolescent marijuana users. Psychopharmacology (Berl) 194:173-183
67. Umbricht D, Vollenweider FX, Schmid L, Grübel C, Skrabo A, Huber T, Koller R (2003) Effects of the 5-HT2A agonist psilocybin on mismatch negativity generation and AX-continuous performance task: implications for the neuropharmacology of cognitive deficits in schizophrenia. Neuropsychopharmacology 28:170-181
68. Vaidya VA, Marek GJ, Aghajanian GK, Duman RS (1997) 5-HT2A receptor-mediated regulation of brain-derived neurotrophic factor mRNA in the hippocampus and the neocortex. J Neurosci 17:2785-2795
69. Vollenweider FX, Kometer M (2010) The neurobiology of psychedelic drugs: implications for the treatment of mood disorders. Nat Rev Neurosci 11:642-651
70. Vollenweider FX, Leenders KL, Scharfetter C, Maguire P, Stadelmann O, Angst J (1997) Positron emission tomography and fluorodeoxyglucose studies of metabolic hyperfrontality and psychopathology in the psilocybin model of psychosis. Neuropsychopharmacology 16:357-372
71. Vollenweider FX, Vollenweider-Scherpenhuyzen MF, Bäbler A, Vogel H, Hell D (1998) Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. Neuroreport 9:3897-3902
72. Vollenweider FX, Csomor PA, Knappe B, Geyer MA, Quednow BB (2007) The effects of the preferential 5-HT2A agonist psilocybin on prepulse inhibition of startle in healthy human volunteers depend on interstimulus interval. Neuropsychopharmacology 32:1876-1887
73. Wackermann J, Wittmann M, Hasler F, Vollenweider FX (2008) Effects of varied doses of psilocybin on time interval reproduction in human subjects. Neurosci Lett 435:51-55
74. Wechsler D (1997) Wechsler Adult Intelligence Scale-III (WAIS-III). The Psychological Corporation, San Antonio, TX
75. Williams GV, Srinivas GR, Goldman-Rakic PS (2002) The pshysiological role of the 5-HT2A in working memory. J Neurosci 22:2843-2854
76. Wittmann M, Carter O, Hasler F, Cahn BR, Grimberg U, Spring P, Hell D, Flohr H, Vollenweider FX (2007) Effects of psilocybin on time perception and temporal control of behavior in humans. J Psychopharmacol 21:50-64